We found that pitolisant, a selective H3R antagonist that is routinely used for the treatment of narcolepsy exhibits the highest affinity for HDAC2 binding site with the embodiment of exemplary HDAC2 pharmacophore, which gave a structural hypothesis for the selection of dual-active inhibitors [52]. The gene discussed is HRH3; the disease is narcolepsy.